Cargando…

How Will Aducanumab Approval Impact AD Research?

Detalles Bibliográficos
Autores principales:	Weiner, Michael W., Aisen, P. S., Beckett, L. A., Green, R. C., Jagust, W., Morris, J. C., Okonkwo, O., Perrin, R. J., Petersen, R. C., Rivera Mindt, M., Saykin, A. J., Shaw, L. M., Toga, A. W., Trojanowski, J. Q.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295641/ https://www.ncbi.nlm.nih.gov/pubmed/34585209 http://dx.doi.org/10.14283/jpad.2021.46

Ejemplares similares

Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community‐engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4
por: Weiner, Michael W., et al.
Publicado: (2022)

Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease
por: Veitch, Dallas P., et al.
Publicado: (2021)

Aducanumab: Appropriate Use Recommendations
por: Cummings, J., et al.
Publicado: (2021)

Aducanumab: Appropriate Use Recommendations Update
por: Cummings, J., et al.
Publicado: (2022)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Topical Insights Into the Post-Approval Controversies of Aducanumab
por: Kumar, Dhiraj, et al.
Publicado: (2021)

Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum
por: Tosun, Duygu, et al.
Publicado: (2021)

Aducanumab: What about the Patient?
por: Petersen, Ronald C.
Publicado: (2021)

The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI)
por: Risacher, Shannon L., et al.
Publicado: (2013)

Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer’s disease
por: Nho, Kwangsik, et al.
Publicado: (2016)

Consensus Statement Regarding the Application of Biogen to Health Canada for Approval of Aducanumab
por: Chertkow, Howard, et al.
Publicado: (2021)

Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer’s disease in veterans, using the Alzheimer’s Disease Neuroimaging Initiative
por: Weiner, Michael W., et al.
Publicado: (2014)

Detection of β-amyloid positivity in Alzheimer’s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers
por: Tosun, Duygu, et al.
Publicado: (2021)

Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer’s disease
por: Nho, Kwangsik, et al.
Publicado: (2017)

Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Is Aducanumab for LMICs? Promises and Challenges
por: Gunawardena, Illangage P. C., et al.
Publicado: (2021)

Tackling a Major Deficiency of Diversity in Alzheimer’s Disease Therapeutic Trials: An CTAD Task Force Report
por: Raman, Rema, et al.
Publicado: (2022)

Aducanumab for Alzheimer’s disease?
por: Walsh, Sebastian, et al.
Publicado: (2021)

Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease
por: Zissimopoulos, Julie, et al.
Publicado: (2022)

Head injury is associated with tau deposition on PET in MCI and AD patients
por: Risacher, Shannon L., et al.
Publicado: (2021)

Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey
por: DiStefano, Michael J., et al.
Publicado: (2022)

Aducanumab: Appropriate use recommendations
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
por: Arndt, Joseph W., et al.
Publicado: (2018)

APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study
por: Ramanan, Vijay K., et al.
Publicado: (2013)

Aducanumab: evidence from clinical trial data and controversies
por: Tampi, Rajesh R, et al.
Publicado: (2021)

Practical Considerations in the Administration of Aducanumab for the Neurologist
por: Coerver, Katherine, et al.
Publicado: (2022)

Aducanumab—Hope or Disappointment for Alzheimer’s Disease
por: Wojtunik-Kulesza, Karolina, et al.
Publicado: (2023)

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
por: Tolar, Martin, et al.
Publicado: (2020)

Enhanced delivery of a low dose of aducanumab via FUS in 5×FAD mice, an AD model
por: Kong, Chanho, et al.
Publicado: (2022)

The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI‐3 updates and global perspectives
por: Weber, Christopher J., et al.
Publicado: (2021)

Estimated Annual Spending on Aducanumab in the US Medicare Program
por: Mafi, John N., et al.
Publicado: (2022)

Re: Aducanumab-Related ARIA: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2023)

Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022)

FASTKD2 is associated with memory and hippocampal structure in older adults
por: Ramanan, Vijay K, et al.
Publicado: (2014)

Influence of Genetic Variation on Plasma Protein Levels in Older Adults Using a Multi-Analyte Panel
por: Kim, Sungeun, et al.
Publicado: (2013)

Should Canadian patients look forward to aducanumab for Alzheimer disease?
por: Watt, Jennifer A., et al.
Publicado: (2021)

Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review
por: Beshir, Semira Abdi, et al.
Publicado: (2022)

Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
por: Vaz, Miguel, et al.
Publicado: (2022)

Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer’s Disease
por: Herring, William L., et al.
Publicado: (2021)

Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers
por: Shen, Li, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_sb4bvcumv9eub01t4v688kha3r